Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of stress radionuclide myocardial perfusion imaging

Panithaya Chareonthaitawee, MD
J. Wells Askew, MD
Section Editors
Patricia A Pellikka, MD, FACC, FAHA, FASE
Gary V Heller, MD, PhD, FACC, MASNC
Deputy Editor
Brian C Downey, MD, FACC


Radionuclide myocardial perfusion imaging (rMPI) enables evaluation of cardiac perfusion and function at rest and during dynamic exercise or pharmacologic stress for the diagnosis and management of patients with known or suspected coronary heart disease. Radionuclide MPI requires the administration of a radioactive perfusion tracer (also called a radiopharmaceutical or radioisotope), usually intravenously, and a special camera system, single-photon emission computed tomography (SPECT), or positron emission tomography (PET), to detect the gamma photons. Myocardial perfusion images are usually acquired at rest and following stress, with increasing adoption of stress-only imaging, and many available combinations of one- versus two-day rest-first versus stress-first protocols, as discussed below. A specialized computer program reconstructs the acquired images into standard displays (image 1).

Radionuclide MPI provides important information on rest and post-stress myocardial perfusion, viability, and global and regional left ventricular systolic function, which generally signify the presence and extent of underlying coronary artery disease. In addition, rMPI is a powerful tool for risk stratification of patients with known or suspected coronary artery disease.

Resting rMPI provides information on the presence or absence of myocardial infarction and viability. To detect the presence and extent of myocardial ischemia, a radioisotope must also be administered under conditions of stress, and rest and stress images can then be compared. Stress testing in conjunction with rMPI is accomplished using either exercise (treadmill or bicycle), pharmacologic agents (preferably vasodilators, but if contraindicated, dobutamine), or a combination of both vasodilator stress and low-level exercise.

An overview of the indications, contraindications, techniques, and safety of stress rMPI will be provided here (table 1). Exercise treadmill testing and stress echocardiography, as well as the advantages and disadvantages of stress rMPI as compared with other stress modalities, are discussed separately. (See "Exercise ECG testing: Performing the test and interpreting the ECG results" and "Overview of stress echocardiography" and "Stress testing for the diagnosis of obstructive coronary heart disease" and "Selecting the optimal cardiac stress test".)


There are several established indications for stress radionuclide myocardial perfusion imaging (rMPI) [1-3]:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Dec 24, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20:1021.
  2. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011; 57:1126.
  3. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 63:380.
  4. Leaker BR, O'Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008; 15:329.
  5. Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008; 15:319.
  6. Mahmarian JJ, Shaw LJ, Filipchuk NG, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol 2006; 48:2448.
  7. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41:159.
  8. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.
  9. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260.
  10. 2009 ASNC imaging guidelines for nuclear cardiology procedures, section on "Stress protocols and tracers" http://www.asnc.org/imageuploads/ImagingGuidelinesStressProtocols021109.pdf (Accessed on September 27, 2010).
  11. Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al. Stress protocols and tracers. J Nucl Cardiol 2006; 13:e80.
  12. Chan SY, Brunken RC, Czernin J, et al. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 1992; 20:979.
  13. Wilson RF, Wyche K, Christensen BV, et al. Effects of adenosine on human coronary arterial circulation. Circulation 1990; 82:1595.
  14. Trochu JN, Zhao G, Post H, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003; 41:132.
  15. Sunderland JJ, Pan XB, Declerck J, Menda Y. Dependency of cardiac rubidium-82 imaging quantitative measures on age, gender, vascular territory, and software in a cardiovascular normal population. J Nucl Cardiol 2015; 22:72.
  16. Voudris V, Manginas A, Vassilikos V, et al. Coronary flow velocity changes after intravenous dipyridamole infusion: measurements using intravascular Doppler guide wire. A documentation of flow inhomogeneity. J Am Coll Cardiol 1996; 27:1148.
  17. Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol 1990; 15:459.
  18. Klocke FJ. Cognition in the era of technology: "seeing the shades of gray". J Am Coll Cardiol 1990; 16:763.
  19. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 1997; 79:2.
  20. Johnston DL, Scanlon PD, Hodge DO, et al. Pulmonary function monitoring during adenosine myocardial perfusion scintigraphy in patients with chronic obstructive pulmonary disease. Mayo Clin Proc 1999; 74:339.
  21. Thomas GS, Miyamoto MI. Should simultaneous exercise become the standard for adenosine myocardial perfusion imaging? Am J Cardiol 2004; 94:3D.
  22. Knabb RM, Gidday JM, Ely SW, et al. Effects of dipyridamole on myocardial adenosine and active hyperemia. Am J Physiol 1984; 247:H804.
  23. McLaughlin DP, Beller GA, Linden J, et al. Hemodynamic and metabolic correlates of dipyridamole-induced myocardial thallium-201 perfusion abnormalities in multivessel coronary artery disease. Am J Cardiol 1994; 73:1159.
  24. Lin LF, Cheng CY, Hou CH, et al. Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol 2014; 21:563.
  25. Ahlberg AW, Baghdasarian SB, Athar H, et al. Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging. J Nucl Cardiol 2008; 15:42.
  26. Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009; 2:959.
  27. Cerqueira MD, Nguyen P, Staehr P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008; 1:307.
  28. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14:645.
  29. Thomas GS, Thompson RC, Miyamoto MI, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009; 16:63.
  30. Uren NG, Melin JA, De Bruyne B, et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994; 330:1782.
  31. Rossen JD, Quillen JE, Lopez AG, et al. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 1991; 18:485.
  32. Dilsizian V, Gewirtz H, Paivanas N, et al. Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies. J Nucl Cardiol 2015; 22:1198.
  33. Abreu A, Mahmarian JJ, Nishimura S, et al. Tolerance and safety of pharmacologic coronary vasodilation with adenosine in association with thallium-201 scintigraphy in patients with suspected coronary artery disease. J Am Coll Cardiol 1991; 18:730.
  34. Cerqueira MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994; 23:384.
  35. Alkoutami GS, Reeves WC, Movahed A. The frequency of atrioventricular block during adenosine stress testing in young, middle-aged, young-old, and old-old adults. Am J Geriatr Cardiol 2001; 10:159.
  36. Lette J, Tatum JL, Fraser S, et al. Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995; 2:3.
  37. Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 1990; 81:1205.
  38. Geleijnse ML, Elhendy A, Fioretti PM, Roelandt JR. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000; 36:2017.
  39. Leppo JA. Comparison of pharmacologic stress agents. J Nucl Cardiol 1996; 3:S22.
  40. Candell-Riera J, Santana-Boado C, Castell-Conesa J, et al. Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease. J Am Coll Cardiol 1997; 29:531.
  41. Holly TA, Satran A, Bromet DS, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nucl Cardiol 2003; 10:291.
  42. Vitola JV, Brambatti JC, Caligaris F, et al. Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging. J Nucl Cardiol 2001; 8:652.
  43. Cabrera R, Husain Z, Palani G, et al. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging. J Nucl Cardiol 2013; 20:336.
  44. Casale PN, Guiney TE, Strauss HW, Boucher CA. Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging. Am J Cardiol 1988; 62:799.
  45. Pennell DJ, Mavrogeni SI, Forbat SM, et al. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995; 25:1300.
  46. Thomas GS, Prill NV, Majmundar H, et al. Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol 2000; 7:439.
  47. Cramer MJ, Verzijlbergen JF, van der Wall EE, et al. Comparison of adenosine and high-dose dipyridamole both combined with low-level exercise stress for 99Tcm-MIBI SPET myocardial perfusion imaging. Nucl Med Commun 1996; 17:97.
  48. Rossen JD, Simonetti I, Marcus ML, Winniford MD. Coronary dilation with standard dose dipyridamole and dipyridamole combined with handgrip. Circulation 1989; 79:566.
  49. Müller P, Czernin J, Choi Y, et al. Effect of exercise supplementation during adenosine infusion on hyperemic blood flow and flow reserve. Am Heart J 1994; 128:52.
  50. Czernin J, Auerbach M, Sun KT, et al. Effects of modified pharmacologic stress approaches on hyperemic myocardial blood flow. J Nucl Med 1995; 36:575.
  51. Tadamura E, Iida H, Matsumoto K, et al. Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men. J Am Coll Cardiol 2001; 37:130.
  52. Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006; 48:1029.
  53. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006; 13:24.
  54. Dorbala S, Hachamovitch R, Curillova Z, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging 2009; 2:846.
  55. DePuey EG, Rozanski A. Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995; 36:952.
  56. Hendel RC, Berman DS, Cullom SJ, et al. Multicenter clinical trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocardial perfusion imaging. Circulation 1999; 99:2742.
  57. Hendel RC, Corbett JR, Cullom SJ, et al. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol 2002; 9:135.
  58. Duvall WL, Baber U, Levine EJ, et al. A model for the prediction of a successful stress-first Tc-99m SPECT MPI. J Nucl Cardiol 2012; 19:1124.
  59. Chow BJ, Ananthasubramaniam K, dekemp RA, et al. Comparison of treadmill exercise versus dipyridamole stress with myocardial perfusion imaging using rubidium-82 positron emission tomography. J Am Coll Cardiol 2005; 45:1227.
  60. Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol 2010; 17:709.
  61. Mieres JH, Gulati M, Bairey Merz N, et al. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation 2014; 130:350.